Larimar Therapeutics (LRMR) announced 25 mg and 50 mg data from the ongoing long-term open label study evaluating daily subcutaneous injections of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback